GlaxoSmithKline MENA Move Highlights EM View

Multinational drugmaker GlaxoSmithKline (GSK) has strengthened its position in the Middle East by purchasing the Bristol-Myers Squibb (BMS) branded generics business in selected countries at a value of US$23.2mn. CFWbelieves that the acquisition will significantly increase GSK's revenues in the region, and bolster its emerging markets portfolio in line with its growth strategy.

To read the full article, please choose one of the following options: